Characterization of choline kinase in human endothelial cells

NMR in Biomedicine

Volumn 26, Issue 11, 2013, Pages 1501-1507

  Mori, Noriko ^a   Gadiya, Mayur ^a   Wildes, Flonné ^a   Krishnamachary, Balaji ^a   Glunde, Kristine ^a,b   Bhujwalla, Zaver M ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Angiogenesis; Breast cancer; Choline kinase; Endothelial cells; MRS; Phosphocholine; Proliferation

Indexed keywords

ANGIOGENESIS; BREAST CANCER; CHOLINE KINASE; MRS; PHOSPHOCHOLINE; PROLIFERATION;

CELL PROLIFERATION; DISEASES; ENDOTHELIAL CELLS; ENZYMES; PROTEINS; RNA; TUMORS;

MOLECULAR BIOLOGY;

CHOLINE KINASE; PHOSPHORYLCHOLINE; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CELL DENSITY; CELL PROLIFERATION; CELL VIABILITY; DOWN REGULATION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSIENT TRANSFECTION; UMBILICAL VEIN ENDOTHELIAL CELL;

LENTIVIRUS; MUS;

ANGIOGENESIS; BREAST CANCER; CHOLINE KINASE; ENDOTHELIAL CELLS; MRS; PHOSPHOCHOLINE; PROLIFERATION;

ANIMALS; CELL EXTRACTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHOLINE KINASE; DOWN-REGULATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84885951161     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.2983     Document Type: Article

References (30)

1. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed. 1992; 5: 303-324.
2. Aoyama C, Liao H, Ishidate K. Structure and function of choline kinase isoforms in mammalian cells. Prog. Lipid Res. 2004; 43: 266-281.
3. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res. 1999; 59: 80-84.
4. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res. 2001; 61: 3599-3603.
5. Ramirez de Molina A, Gutierrez R, Ramos MA, Silva JM, Silva J, Bonilla F, Sanchez JJ, Lacal JC. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene 2002; 21: 4317-4322.
6. Ramirez de Molina A, Sarmentero-Estrada J, Belda-Iniesta C, Taron M, Ramirez de Molina V, Cejas P, Skrzypski M, Gallego-Ortega D, de Castro J, Casado E, Garcia-Cabezas MA, Sanchez JJ, Nistal M, Rosell R, Gonzalez-Baron M, Lacal JC. Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol. 2007; 8: 889-897.
7. Hernando E, Sarmentero-Estrada J, Koppie T, Belda-Iniesta C, Ramirez de Molina V, Cejas P, Ozu C, Le C, Sanchez JJ, Gonzalez-Baron M, Koutcher J, Cordon-Cardo C, Bochner BH, Lacal JC, Ramirez de Molina A. A critical role for choline kinase-alpha in the aggressiveness of bladder carcinomas. Oncogene 2009; 28: 2425-2435.
8. Iorio E, Ricci A, Bagnoli M, Pisanu ME, Castellano G, Di Vito M, Venturini E, Glunde K, Bhujwalla ZM, Mezzanzanica D, Canevari S, Podo F. Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells. Cancer Res. 2010; 70: 2126-2135.
9. Glunde K, Jie C, Bhujwalla ZM. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res. 2004; 64: 4270-4276.
10. Yalcin A, Clem B, Makoni S, Clem A, Nelson K, Thornburg J, Siow D, Lane AN, Brock SE, Goswami U, Eaton JW, Telang S, Chesney J. Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling. Oncogene 2010; 29: 139-149.
11. Glunde K, Raman V, Mori N, Bhujwalla ZM. RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res. 2005; 65: 11 034-11 043.
12. Eliyahu G, Kreizman T, Degani H. Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int. J. Cancer. 2007; 120: 1721-1730.
13. Lacal JC. Choline kinase: a novel target for antitumor drugs. IDrugs. 2001; 4: 419-426.
14. Hernandez-Alcoceba R, Fernandez F, Lacal JC. In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery. Cancer Res. 1999; 59: 3112-3118.
15. Ramirez de Molina A, Banez-Coronel M, Gutierrez R, Rodriguez-Gonzalez A, Olmeda D, Megias D, Lacal JC. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res. 2004; 64: 6732-6739.
16. Rodriguez-Gonzalez A, Ramirez de Molina A, Fernandez F, Ramos MA, del Carmen Nunez M, Campos J, Lacal JC. Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells. Oncogene 2003; 22: 8803-8812.
17. Rodriguez-Gonzalez A, Ramirez de Molina A, Fernandez F. Lacal JC. Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action. Oncogene 2004; 23: 8247-8259.
18. Krishnamachary B, Glunde K, Wildes F, Mori N, Takagi T, Raman V, Bhujwalla ZM. Noninvasive detection of lentiviral-mediated choline kinase targeting in a human breast cancer xenograft. Cancer Res. 2009; 69: 3464-3471.
19. Mori N, Glunde K, Takagi T, Raman V, Bhujwalla ZM. Choline kinase down-regulation increases the effect of 5-fluorouracil in breast cancer cells. Cancer Res. 2007; 67: 11 284-11 290.
20. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J. Natl. Cancer Inst. 1990; 82: 4-6.
21. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971; 285: 1182-1186.
22. Ribatti D. Judah Folkman, a pioneer in the study of angiogenesis. Angiogenesis 2008; 11: 3-10.
23. Wu G, Aoyama C, Young SG, Vance DE. Early embryonic lethality caused by disruption of the gene for choline kinase alpha, the first enzyme in phosphatidylcholine biosynthesis. J. Biol. Chem. 2008; 283: 1456-1462.
24. Wu G, Sher RB, Cox GA, Vance DE. Understanding the muscular dystrophy caused by deletion of choline kinase beta in mice. Biochim. Biophys. Acta 2009; 1791: 347-356.
25. Sher RB, Aoyama C, Huebsch KA, Ji S, Kerner J, Yang Y, Frankel WN, Hoppel CL, Wood PA, Vance DE, Cox GA. A rostrocaudal muscular dystrophy caused by a defect in choline kinase beta, the first enzyme in phosphatidylcholine biosynthesis. J. Biol. Chem. 2006; 281: 4938-4948.
26. Glunde K, Serkova NJ. Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. Pharmacogenomics 2006; 7: 1109-1123.
27. Gallego-Ortega D, Ramirez de Molina A, Ramos MA, Valdes-Mora F, Barderas MG, Sarmentero-Estrada J, Lacal JC. Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatment. PLoS One 2009; 4: e7819.
28. Mori N, Natarajan K, Chacko VP, Artemov D, Bhujwalla ZM. Choline phospholipid metabolites of human vascular endothelial cells altered by cyclooxygenase inhibition, growth factor depletion, and paracrine factors secreted by cancer cells. Mol. Imaging, 2003; 2: 124-130.
29. -ΔΔCt method. Methods 2001; 25: 402-408.
30. Dean Fraga TM, Fenster S. UNIT 10.3 Real-Time PCR. Current Protocols Essential Laboratory Techniques. John Wiley and Sons: Hoboken, NJ; 2008, 10.3.1-10.3.33.